Lombardi: Stock Market Commentary & Forecasts, Financial & Economic Analysis Since 1986

Is the Run in Biotechnology Stocks Over?

Monday, March 25th, 2013
By for Profit Confidential

Run in Biotechnology Stocks OverOne of the stock market’s strongest sectors over the last few years has been biotechnology stocks. It’s a very tough group in which to be a speculator, because you cannot predict discoveries or approvals. What you can do, though, is play the news flow while gauging sentiment in the stock market.

The NASDAQ Biotechnology Index has been on a tear for the last four years, and according to Reuters, the U.S. Food and Drug Administration (FDA) approved 39 new drugs and biological products last year. This compares to 30 in 2011 and 21 in 2010. It is the highest number, beating the previous high reached in 1996, when 35 new drugs were approved. (Source: Hirschler, B. and Humer, C., “FDA new drug approvals hit 16-year high in 2012,” Reuters, last accessed March 21, 2013.)

On the stock market, anything can happen with biotechnology stocks, and you can lose your shirt pretty quickly. Opko Health, Inc. (NYSE/OPK) is one of those biotechnology stocks that perfectly illustrate the challenges of trading in the group.

Opko is a biotechnology aggregator; it has its hand in a lot of developments. The company is run by Dr. Phillip Frost, who became a billionaire when he sold his last pharmaceutical company to a major drug manufacturer. Opko’s stock chart is featured below:

OPK Opko Health Inc stock market chart

Chart courtesy of www.StockCharts.com

  • 100% Profit in Your Pocket Every 14 Days or Less with This Never-Ending Winning Streak

    Any stocks in your portfolio make you 100% or more this year? Let me tell you about 25 of them! In 2013, 25 of our positions reached gains in excess of 100% each. Average profit per pick at their high was 215.6%!

    Our 100% Letter could make you more money in 2014 than ever before! Learn about it here.

For months and months, Frost was buying shares in Opko Health on the stock market (all open market, public and documented), but the price didn’t move. This went on and on until the company announced an expanded collaboration with Bristol Myers-Squibb Company (NYSE/BMY) for one of its diagnostic tests. Then, bam! Opko’s shares exploded on the stock market.

Biotechnology stocks are like this, but the tough part is that you have to be watching them all the time. (See “High Risk, High Reward—Two Great Companies for Traders.”) They can also move in the opposite direction with equal fervor.

The NASDAQ Biotechnology Index has continued momentum. The good thing about most biotechnology stocks is that they have little correlation to the broader stock market; they dance to their own tune, for sure.

Because there is so much money in pharmaceuticals, institutional participation within the sector is very strong. Among developing biotechnology stocks, virtually the only players are institutions (and billionaires).

A trader can piggyback on the news in biotechnology stocks, but you have to be prepared to quickly jump ship. The action in this group continues to have momentum, and FDA approvals should maintain a strong pace this year. The whole sector is, of course, 100% speculative.

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

This is an entirely free service. No credit card required.

We hate spam as much as you do.
Check out our privacy policy.

Mitchell Clark - Equity Markets Specialist, Financial AdvisorMitchell Clark, B. Comm. is a Senior Editor at Lombardi Financial specializing in large- and micro-cap stocks. He’s the editor of a variety of popular Lombardi Financial newsletters, such as Income for Life and Micro-Cap Reporter. Mitchell, who has been with Lombardi Financial for 17 years, won the Jack Madden Prize in economic history and is a long-time student of equity markets. Prior to joining Lombardi, Mitchell was as a stock broker for a large investment bank. Add Mitchell Clark to your Google+ circles

The Great Crash of 2014

A stock market crash bigger than what happened in 2008 and early 2009 is headed our way.

In fact, we are predicting this crash will be even more devastating than the 1929 crash…

…the ramifications of which will hit the economy and Americans deeper than anything we’ve ever seen.

Our 27-year-old research firm feels so strongly about this, we’ve just produced a video to warn investors called, “The Great Crash of 2014.”

In case you are not familiar with our research work on the stock market:

In late 2001, in the aftermath of 9/11, we told our clients to buy small-cap stocks. They rose about 100% after we made that call.

We were one of the first major advisors to turn bullish on gold.

Throughout 2002, we urged our readers to buy gold stocks; many of which doubled and even tripled in price.

In November of 2007, we started begging our customers to get out of the stock market. Shortly afterwards, it was widely recognized that October 2007 was the top for stocks.

We correctly predicted the crash in the stock market of 2008 and early 2009.

And in March of 2009, we started telling our readers to jump into small caps. The Russell 2000 gained about 175% from when we made that call in 2009 to today.

Many investors will find our next prediction hard to believe until they see all the proof we have to back it up.

Even if you don’t own stocks, what’s about to happen will affect you!

I urge you to be among the first to get our next major prediction.
See it here now in this just-released alarming video.